174 related articles for article (PubMed ID: 32898246)
1. Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2.
Sarode R; Fukutake K; Yasaka M; Tortorici MA; Mangione A; Pfister M; Cuker A
Blood Adv; 2020 Sep; 4(17):4208-4216. PubMed ID: 32898246
[TBL] [Abstract][Full Text] [Related]
2. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy.
Sobrino Jiménez C; Romero-Garrido JA; García-Martín Á; Quintana-Díaz M; Jiménez-Vicente C; González-Del Valle L; Herrero Ambrosio A; Benedí-González J
Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e66-e71. PubMed ID: 32591479
[TBL] [Abstract][Full Text] [Related]
4. A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal.
Kerebel D; Joly LM; Honnart D; Schmidt J; Galanaud D; Negrier C; Kursten F; Coriat P;
Crit Care; 2013 Jan; 17(1):R4. PubMed ID: 23305460
[TBL] [Abstract][Full Text] [Related]
5. Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal: Does One Dose Fit All?
Schwebach AA; Waybright RA; Johnson TJ
Pharmacotherapy; 2019 May; 39(5):599-608. PubMed ID: 30892733
[TBL] [Abstract][Full Text] [Related]
6. INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma.
Hood C; Goldstein JN; Milling TJ; Refaai MA; Bajcic P; Goldstein B; Sarode R
Blood Adv; 2023 May; 7(10):2206-2213. PubMed ID: 36574241
[TBL] [Abstract][Full Text] [Related]
7. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
Bitonti MT; Rumbarger RL; Absher RK; Curran LM
J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
[TBL] [Abstract][Full Text] [Related]
9. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate for Bleeding Complications of Vitamin K Antagonists-The PROPER3 Randomized Clinical Trial.
Abdoellakhan RA; Khorsand N; Ter Avest E; Lameijer H; Faber LM; Ypma PF; Nieuwenhuizen L; Veeger NJGM; Meijer K
Ann Emerg Med; 2022 Jan; 79(1):20-30. PubMed ID: 34535300
[TBL] [Abstract][Full Text] [Related]
10. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?
Mangram A; Oguntodu OF; Dzandu JK; Hollingworth AK; Hall S; Cung C; Rodriguez J; Yusupov I; Barletta JF
J Crit Care; 2016 Jun; 33():252-6. PubMed ID: 27021851
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
[TBL] [Abstract][Full Text] [Related]
12. Roles of Four-Factor Prothrombin Complex Concentrate in the Management of Critical Bleeding.
Tanaka KA; Shettar S; Vandyck K; Shea SM; Abuelkasem E
Transfus Med Rev; 2021 Oct; 35(4):96-103. PubMed ID: 34551881
[TBL] [Abstract][Full Text] [Related]
13. Four-factor prothrombin complex concentrate dose response relationship with INR for warfarin reversal.
Yohe AS; Livings SE
Am J Emerg Med; 2019 Aug; 37(8):1534-1538. PubMed ID: 31130370
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of 4-factor Prothrombin Complex Concentrate in Patients With Liver Disease and Nonvitamin K Antagonist-Related Coagulopathy: A Retrospective Study.
Dodhiawala PB; Pribyl K; Larson J; Vakayil V; Chandrashekar M; Lord A; Welbig J; Zantek ND; Martin D; Harmon JV
Clin Appl Thromb Hemost; 2023; 29():10760296231198038. PubMed ID: 37649304
[TBL] [Abstract][Full Text] [Related]
15. Hemostatic Efficacy and Safety of Weight-Based Versus Fixed-Dose 4F-PCC for Vitamin K Antagonist Reversal.
Milkovits AE; Sugrue D; Faris J; Schad JL; McAllister KB
J Pharm Pract; 2024 Jan; ():8971900241228779. PubMed ID: 38241183
[No Abstract] [Full Text] [Related]
16. Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice.
Desmettre T; Dehours E; Samama CM; Jhundoo S; Pujeau F; Guillaudin C; Hecquart C; Clerson P; Crave JC; Jaussaud R
Crit Care; 2012 Oct; 16(5):R185. PubMed ID: 23036234
[TBL] [Abstract][Full Text] [Related]
17. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose.
Holland L; Warkentin TE; Refaai M; Crowther MA; Johnston MA; Sarode R
Transfusion; 2009 Jun; 49(6):1171-7. PubMed ID: 19210325
[TBL] [Abstract][Full Text] [Related]
18. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Sin JH; Berger K; Lesch CA
J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
[TBL] [Abstract][Full Text] [Related]
19. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.
Pabinger I; Brenner B; Kalina U; Knaub S; Nagy A; Ostermann H;
J Thromb Haemost; 2008 Apr; 6(4):622-31. PubMed ID: 18208533
[TBL] [Abstract][Full Text] [Related]
20. Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol.
Fuh L; Goldstein JN; Hayes BD
J Thromb Thrombolysis; 2020 Jul; 50(1):217-220. PubMed ID: 31707622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
